10:12 AM EST - Oncolytics Biotech Inc : Announced alignment with the U.S. Food and Drug Administration regarding the design of its pivotal study of pelareorep in combination with standard-of-care therapy for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). Oncolytics Biotech Inc
shares N.ONCY are trading up one cent at $1.04.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=6769599894970587
